Jun 2026 (Q2 FY26) — Aug 13, 2026
Cellebrite Q2 FY26 — Leadership Transition Amidst Missed ARR Targets and Strong AI Product Launch
Read the full callCellebrite earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Price
1Y: $18.18 on 17 Oct 2025 → $11.15. High $19.28 (13 Nov 2025), low $10.44 (17 Aug 2026).
Overview
Call summaries
Cellebrite Q2 FY26 — Leadership Transition Amidst Missed ARR Targets and Strong AI Product Launch
Read the full callEvery analysed call
Financials
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | — | — | — | — |
| Reserves | — | 28 | 78 | 199 | 118 | -165 | -87 |
| Total liabilities | — | 199 | 413 | 329 | 499 | 355 | 455 |
| Fixed assets | — | 16 | 17 | 17 | 16 | 17 | 22 |
| Investments | — | — | 0 | 45 | 39 | 102 | 152 |
| Total assets | — | 364 | 340 | 403 | 533 | 691 | 939 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 16 | 67 | 36 | 21 | 102 | 132 | 174 |
| Cash from investing | -47 | -6 | 45 | -91 | -23 | -149 | -268 |
| Cash from financing | 76 | -9 | -68 | 14 | 22 | 21 | 25 |
| Capital expenditure | -6 | -6 | -5 | -7 | -5 | -9 | -13 |
| Free cash flow | 10 | 60 | 31 | 14 | 97 | 124 | 160 |
24 filings between May 12, 2026 and Sep 24, 2026.
Purchases
None
No insider bought shares.
Sales
$5.21M
14 sales by 4 insiders
21% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Hogan Thomas E. | — | $4.06M | Aug 25, 2026 |
| Barter David | — | $683.4K | Jul 8, 2026 |
| Jewell Marcus | — | $314.5K | Aug 21, 2026 |
| GEE DAVID NICHOLAS | — | $155.0K | Aug 24, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 24, 2026 | Ramji Shiven Chief Executive Officer | Award | 38,505 | $0 |
| Sep 17, 2026 | Utsumi Ryusuke Director | Award | 15,190 | $0 |
| Sep 17, 2026 | Domnitz Yonatan Director | Award | 15,190 | $0 |
| Sep 17, 2026 | CLAMMER ADAM Director | Award | 15,190 | $0 |
| Sep 17, 2026 | Baudot-Trajtenberg Nadine Director | Award | 15,190 | $0 |
| Sep 17, 2026 | Van Buren Brandon Director | Award | 15,190 | $0 |
| Sep 17, 2026 | Richardson Troy Director | Award | 15,190 | $0 |
| Sep 17, 2026 | Gruber Dafna Director | Award | 15,190 | $0 |
| Aug 25, 2026 | Hogan Thomas E. Insider | Sale | 25,299 | $285.7K |
| Aug 24, 2026 | GEE DAVID NICHOLAS Chief Marketing Officer | Sale 10b5-1 plan | 4,323 | $49.1K |
| Aug 21, 2026 | GEE DAVID NICHOLAS Chief Marketing Officer | Sale | 2,198 | $24.7K |
| Aug 21, 2026 | Jewell Marcus Global Chief Revenue Officer | Sale | 12,562 | $141.2K |
| Aug 12, 2026 | Hogan Thomas E. Chief Executive Officer | Sale | 139,713 | $2.15M |
| Aug 12, 2026 | GEE DAVID NICHOLAS Chief Marketing Officer | Sale | 230 | $3.7K |
| Aug 12, 2026 | Jewell Marcus Global Chief Revenue Officer | Sale | 411 | $6.6K |
| Aug 11, 2026 | Hogan Thomas E. Chief Executive Officer | Award | 339,484 | $0 |
| Jul 8, 2026 | Barter David Chief Financial Officer | Sale | 41,734 | $683.4K |
| Jul 2, 2026 | Hogan Thomas E. Chief Executive Officer | Sale | 103,188 | $1.63M |
| May 21, 2026 | GEE DAVID NICHOLAS Chief Marketing Officer | Sale 10b5-1 plan | 2,243 | $29.4K |
| May 21, 2026 | GEE DAVID NICHOLAS Chief Marketing Officer | Sale 10b5-1 plan | 3,430 | $45.1K |
| May 18, 2026 | Jewell Marcus Global Chief Revenue Officer | Sale | 12,658 | $161.7K |
| May 12, 2026 | GEE DAVID NICHOLAS Chief Marketing Officer | Sale | 228 | $3.0K |
| May 12, 2026 | Jewell Marcus Global Chief Revenue Officer | Sale | 383 | $5.0K |
| May 12, 2026 | Ramji Shiven President Products & Tech | Award | 423,550 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow Cellebrite DI Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading